Press release content from Globe Newswire. The AP news staff was not involved in its creation.
ERYTECH to Present at the H.C. Wainwright Virtual BioConnect 2021 Conference
Erytech Pharma S.A.January 6, 2021 GMT
ERYTECH to Present at the H.C. Wainwright Virtual BioConnect 2021 Conference
Lyon (France) and Cambridge, MA (U.S.), January 6, 2021 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, announced today that CEO, Gil Beyen, will present at the H.C. Wainwright Virtual BioConnect 2021 in a pre-recorded corporate overview presentation.
Beginning January 11th, a pre-recorded presentation by company management will be available for on-demand viewing by registered attendees anytime through January 14th by accessing the HC Wainwright Virtual Conference portal. Those interested in registering for the conference can do so here: https://hcwev
ERYTECH Completes Enrollment in TRYbeCA-1 Phase 3 Trial in Second-Line Pancreatic Cancer
A total of 510 patients enrolled
Events required to trigger interim superiority analysis accrued
Interim superiority analysis expected in Q1 2021; final analysis in Q4 2021
LYON, France and CAMBRIDGE, Mass., Dec. 14, 2020 (GLOBE NEWSWIRE) ERYTECH Pharma (Nasdaq & Euronext: ERYP),
a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced the completion of enrollment in the TRYbeCA-1 Phase 3 trial in second-line pancreatic cancer.
TRYbeCA-1, the pivotal Phase 3 clinical trial evaluating ERYTECH’s lead product candidate, eryaspase, in second-line metastatic pancreatic cancer, has completed patient enrollment. A total of 510 patients participated in the trial, slightly above the target enrollment of 482 patients.
Erytech Pharma S.A.: ERYTECH Completes Enrollment in TRYbeCA-1 Phase 3 Trial in Second-Line Pancreatic Cancer
Events required to trigger interim superiority analysis accrued
Interim superiority analysis expected in Q1 2021; final analysis in Q4 2021
LYON, France and CAMBRIDGE, Mass., Dec. 14, 2020 (GLOBE NEWSWIRE) ERYTECH Pharma (Nasdaq & Euronext: ERYP),
a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced the completion of enrollment in the TRYbeCA-1 Phase 3 trial in second-line pancreatic cancer.
TRYbeCA-1, the pivotal Phase 3 clinical trial evaluating ERYTECH s lead product candidate, eryaspase, in second-line metastatic pancreatic cancer, has completed patient enrollment. A total of 510 patients participated in the trial, slightly above the target enrollment of 482 patients.
The event will be held virtually, with all corporate and institutional participants joining remotely.
A webcast of the event will be available by clicking here and will be accessible via ERYTECH s website at http://www.erytech.com/investors/webcast/
About ERYTECH and eryaspase
ERYTECH is a clinical-stage biopharmaceutical company developing innovative red blood cell-based therapeutics for severe forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS® platform, which uses a novel technology to encapsulate drug substances inside red blood cells, ERYTECH is developing a pipeline of product candidates for patients with high unmet medical needs. ERYTECH s primary focus is on the development of product candidates that target the altered metabolism of cancer cells by depriving them of amino acids necessary for their growth and survival.
Erytech Pharma S.A.: ERYTECH to Present at the JMP Securities Hematology Summit
ERYTECH Pharma
cells,
t Tuesday December 15
by
The event will be held virtually, with all corporate and institutional participants joining remotely.
A webcast of the event will be available by clicking hereand will be accessible via ERYTECH s website at http://www.erytech.com/investors/webcast/
About ERYTECH and eryaspase
ERYTECH is a clinical-stage biopharmaceutical company developing innovative red blood cell-based therapeutics for severe forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS platform, which uses a novel technology to encapsulate drug substances inside red blood cells, ERYTECH is developing a pipeline of product candidates for patients with high unmet medical needs. ERYTECH s primary focus is on the development of product candidates that target the altered metabolism of cancer cells by depriving them of amino acids necessary for their growth and survival.